# Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant

> **NCT01503515** · PHASE3 · COMPLETED · sponsor: **Children's Oncology Group** · enrollment: 292 (actual)

## Conditions studied

- Fungal Infection
- Hematopoietic and Lymphoid Cell Neoplasm

## Interventions

- **DRUG:** Caspofungin Acetate
- **DRUG:** Fluconazole
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Voriconazole

## Key facts

- **NCT ID:** NCT01503515
- **Lead sponsor:** Children's Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-03-21
- **Primary completion:** 2019-12-31
- **Final completion:** 2021-09-30
- **Target enrollment:** 292 (ACTUAL)
- **Last updated:** 2024-10-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01503515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01503515, "Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01503515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*